Chronic Allograft Nephropathy—A Narrative Review of Its Pathogenesis, Diagnosis, and Evolving Management Strategies

Chronic allograft nephropathy is the leading cause of kidney allograft failure. Clinically, it is characterized by a progressive decline in kidney function, often in combination with proteinuria and hypertension. Histologically, interstitial fibrosis and tubular atrophy, along with features of glomerulosclerosis with occasional double contour appearance, arteriolar hyalinosis, and arteriosclerosis, are characteristic findings. The pathophysiology, though complex and incompletely understood, is thought to involve a sequence of immunologic and non-immunologic injuries eventually leading to tissue remodeling and scarring within the graft. The optimal strategy to prevent chronic allograft nephropathy is to minimize both immune- and non-immune-mediated graft injury.

• Publication year

  2025

• Venue

  Biomedicines

• Publication date

  2025-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/biomedicines13040929PMID 40299546PMCID 12024747
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy, Mechanisms, and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients

  2025cited by this paper
• Interaction Between Cold Ischemia Time and KDPI on Post Renal Transplant Outcomes.

  2024cited by this paper
• A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection.

  2024cited by this paper
• Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study)

  2024cited by this paper
• IFTA Foci Density: An Unrecognized Highly Prognostic Measurement of Fibrosis in Kidney Transplant Biopsies

  2024cited by this paper
• Impact of Kidney Allocation System 250 Policy on One Year Graft Loss.

  2024cited by this paper
• SGLT2 inhibitor in diabetic and non-diabetic renal transplant recipients

  2024cited by this paper
• Advancements in Elastography for Evaluating Fibrosis in Renal Transplants: Current Perspectives

  2024cited by this paper
• Association of early steroid withdrawal with kidney transplant outcomes in first-transplant and retransplant recipients.

  2024cited by this paper
• Chronic Active Antibody-mediated Rejection: Opportunity to Determine the Role of Interleukin-6 Blockade

  2023cited by this paper
• Outcomes of Kidney Perfusion Techniques in Transplantation from Deceased Donors: A Systematic Review and Meta-Analysis

  2023cited by this paper
• Excellent efficacy and beneficial safety during observational 5-year follow-up of rapid steroid withdrawal after renal transplantation (Harmony FU study)

  2023cited by this paper
• Prospective observational study to validate a next-generation sequencing blood RNA signature to predict early kidney transplant rejection.

  2023cited by this paper
• Follow‐up biopsies identify high rates of persistent rejection in pediatric kidney transplant recipients after treatment of T cell‐mediated rejection

  2023cited by this paper
• Improved Early Post-Transplant Outcomes and Organ Use in Kidney Transplant Using Normothermic Regional Perfusion for Donation after Circulatory Death: National Experience in the US.

  2023cited by this paper
• Optimized immunosuppression to prevent graft failure in renal transplant recipients with HLA antibodies (OuTSMART): a randomised controlled trial

  2023cited by this paper
• Non-Traditional Non-Immunological Risk Factors for Kidney Allograft Loss—Opinion

  2023cited by this paper
• How Should Acute T Cell–mediated Rejection of Kidney Transplants be Treated: Importance of Follow-up Biopsy From Kidney Transplantation

  2023cited by this paper
• Application of Real-Time Sound Touch Elastography for Evaluating Chronic Kidney Disease of Transplanted Kidneys.

  2023cited by this paper
• Long-Term Immunological Outcomes of Early Subclinical Inflammation on Surveillance Kidney Allograft Biopsies.

  2022cited by this paper
• The Molecular Diagnosis Might Be Clinically Useful in Discrepant Kidney Allograft Biopsy Findings: An Analysis of Clinical Outcomes

  2022cited by this paper
• 423.3: Long-term Outcomes Following HLA-Incompatible Living Donor Kidney Transplantation

  2022cited by this paper
• Early Effect of the Circular Model of Kidney Allocation in the United States

  2022cited by this paper
• Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design

  2022cited by this paper
• How Should Acute T-cell Mediated Rejection of Kidney Transplants Be Treated: Importance of Follow-up Biopsy

  2022cited by this paper
• Treatment of chronic active T cell‐mediated rejection after kidney transplantation: A retrospective cohort study of 37 transplants

  2022cited by this paper
• Sodium‐glucose cotransporter 2 inhibitors for treatment of diabetes mellitus after kidney transplantation

  2022cited by this paper
• Prognostic Implications of a Morphometric Evaluation for Chronic Changes on All Diagnostic Native Kidney Biopsies

  2022cited by this paper
• Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients: Treatment Response Rates and Value of Early Surveillance Biopsies

  2022cited by this paper
• Chronic Allograft Injury.

  2021cited by this paper
• Transplantation of kidneys after normothermic perfusion: A single center experience

  2021cited by this paper
• Improved short‐term outcomes of kidney transplants in controlled donation after the circulatory determination of death with the use of normothermic regional perfusion

  2021cited by this paper
• Kidney Transplants in Controlled Donation Following Circulatory Death, or Maastricht Type III Donors, With Abdominal Normothermic Regional Perfusion, Optimizing Functional Outcomes

  2021cited by this paper
• Chronic active T cell-mediated rejection is variably responsive to immunosuppressive therapy.

  2021cited by this paper
• Conversion from Calcineurin Inhibitor– to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial

  2021cited by this paper
• A Higher Foci Density of Interstitial Fibrosis and Tubular Atrophy Predicts Progressive CKD after a Radical Nephrectomy for Tumor

  2021cited by this paper
• Beyond the Biopsy: Monitoring Immune Status in Kidney Recipients.

  2021cited by this paper
• Impact of Subclinical and Clinical Kidney Allograft Rejection Within 1 Year Posttransplantation Among Compatible Transplant With Steroid Withdrawal Protocol

  2021cited by this paper
• Do we need to treat chronic active T cell-mediated rejection?

  2021cited by this paper
• The Many Faces of Calcineurin Inhibitor Toxicity-What the FK?

  2020cited by this paper
• The molecular microscope diagnostic system (MMDx) in transplantation: A pathologist’s perspective

  2020cited by this paper
• Eplet Mismatch Load and De Novo Occurrence of Donor-Specific Anti-HLA Antibodies, Rejection, and Graft Failure after Kidney Transplantation: An Observational Cohort Study.

  2020cited by this paper
• i‐IFTA and chronic active T cell–mediated rejection: A tale of 2 (DeKAF) cohorts

  2020cited by this paper
• Early initiation of sodium‐glucose linked transporter inhibitors (SGLT‐2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients

  2020cited by this paper
• A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection.

  2020cited by this paper
• Effect of Optimized Immunosuppression (Including Rituximab) on Anti-Donor Alloresponses in Patients With Chronically Rejecting Renal Allografts

  2020cited by this paper
• Hypothermic machine perfusion is superior to static cold storage in deceased donor kidney transplantation: A meta‐analysis

  2020cited by this paper
• Epitope matching in kidney transplantation: recent advances and current limitations.

  2019cited by this paper
• Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group

  2019cited by this paper
• Multicentre randomised controlled trial protocol of urine CXCL10 monitoring strategy in kidney transplant recipients

  2019cited by this paper
• Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection

  2019cited by this paper
• Clinical Significance of Renal Allograft Protocol Biopsies: A Single Tertiary Center Experience in Malaysia

  2019cited by this paper
• Post-transplant donor specific antibody is associated with poor kidney transplant outcomes only when combined with both T-cell-mediated rejection and non-adherence.

  2019cited by this paper
• The Impact of Early Clinical and Subclinical T Cell-mediated Rejection After Kidney Transplantation.

  2019cited by this paper
• BK polyomavirus in solid organ transplantation—Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

  2019cited by this paper
• Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus

  2019cited by this paper
• Donor-Specific Antibodies in Kidney Transplant Recipients.

  2018cited by this paper
• Mechanisms of Renal Fibrosis.

  2018cited by this paper
• Molecular phenotype of kidney transplant indication biopsies with inflammation in scarred areas

  2018cited by this paper
• Uncontrolled donation after circulatory death: comparison of two kidney preservation protocols on graft outcomes

  2018cited by this paper
• Anti‐C1s monoclonal antibody BIVV009 in late antibody‐mediated kidney allograft rejection—results from a first‐in‐patient phase 1 trial

  2018cited by this paper
• Association of Cold Ischemia Time With Acute Renal Transplant Rejection

  2018cited by this paper
• HLA-DQ Mismatching and Kidney Transplant Outcomes.

  2018cited by this paper
• Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double‐blind clinical trial

  2018cited by this paper
• Human leukocyte antigen matching in organ transplantation: what we know and how can we make it better (Revisiting the past, improving the future)

  2018cited by this paper
• Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss.

  2017cited by this paper
• The Impact of Total Ischemic Time, Donor Age and the Pathway of Donor Death on Graft Outcomes After Deceased Donor Kidney Transplantation

  2017cited by this paper
• Real Time Central Assessment of Kidney Transplant Indication Biopsies by Microarrays: The INTERCOMEX Study

  2017cited by this paper
• A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.

  2017cited by this paper
• Cell-Free DNA and Active Rejection in Kidney Allografts.

  2017cited by this paper
• BK Virus Nephropathy: Histological Evolution by Sequential Pathology

  2017cited by this paper
• Eculizumab Therapy for Chronic Antibody‐Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial

  2017cited by this paper
• Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study.

  2016cited by this paper
• Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors.

  2016cited by this paper
• HLA-DQ Mismatches and Rejection in Kidney Transplant Recipients.

  2016cited by this paper
• Transplantation of kidneys from uncontrolled donation after circulatory determination of death: comparison with brain death donors with or without extended criteria and impact of normothermic regional perfusion

  2016cited by this paper
• The Association Between Broad Antigen HLA Mismatches, Eplet HLA Mismatches and Acute Rejection After Kidney Transplantation

  2016cited by this paper
• Subclinical Rejection in Renal Transplantation: Reappraised

  2016influential reference
• Belatacept and Long-Term Outcomes in Kidney Transplantation.

  2016cited by this paper
• Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.

  2016cited by this paper
• Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.

  2016cited by this paper
• Current outcomes of chronic active antibody mediated rejection - A large single center retrospective review using the updated BANFF 2013 criteria.

  2016cited by this paper
• OriginalClinicalScienceçGeneral The Risk of Transplant Failure With HLA Mismatch in First Adult Kidney Allografts From Deceased Donors

  2016cited by this paper
• Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta‐Analysis

  2016cited by this paper
• Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.

  2015cited by this paper
• Each additional hour of cold ischemia time significantly increases the risk of graft failure and mortality following renal transplantation.

  2015cited by this paper
• The Interplay between Inflammation and Fibrosis in Kidney Transplantation

  2014cited by this paper
• Early Corticosteroid Avoidance in Kidney Transplant Recipients Receiving ATG‐F Induction: 5‐Year Actual Results of a Prospective and Randomized Study

  2014cited by this paper
• Time Course of Pathologic Changes in Kidney Allografts of Positive Crossmatch HLA-Incompatible Transplant Recipients

  2014cited by this paper
• Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.

  2014cited by this paper
• Angiotensin II blockade in kidney transplant recipients.

  2013cited by this paper
• Long‐Term Belatacept Exposure Maintains Efficacy and Safety at 5 Years: Results From the Long‐Term Extension of the BENEFIT Study

  2013cited by this paper
• Microarray Diagnosis of Antibody‐Mediated Rejection in Kidney Transplant Biopsies: An International Prospective Study (INTERCOM)

  2013cited by this paper
• Urinary-cell mRNA profile and acute cellular rejection in kidney allografts.

  2013cited by this paper
• Evolution and Clinical Pathologic Correlations of De Novo Donor‐Specific HLA Antibody Post Kidney Transplant

  2012cited by this paper
• Donor-specific antibodies adversely affect kidney allograft outcomes.

  2012cited by this paper
• Influence of Induction Modality on the Outcome of Deceased Donor Kidney Transplant Recipients Discharged on Steroid-Free Maintenance Immunosuppression

  2012cited by this paper
• De Novo DQ Donor-Specific Antibodies Are Associated With a Significant Risk of Antibody-Mediated Rejection and Transplant Glomerulopathy

  2012cited by this paper
• Kidney Allograft Inflammation and Fibrosis, Causes and Consequences

  2012cited by this paper
• Human leukocyte antigen mismatches associated with increased risk of rejection, graft failure, and death independent of initial immunosuppression in renal transplant recipients

  2012cited by this paper

• Vascular Remodeling in Chronic Rejection: Insights into Transplant Vasculopathy Across Solid Organ Allografts.

  2026cites this paper
• Heart Failure in Kidney Transplant Recipients: Narrative Review of Risk Factors, Therapy, and Current Gaps in Management.

  2026cites this paper
• Delayed graft function as a predictor of chronic allograft dysfunction: a 10-year follow-up study

  2025cites this paper
• Calcineurin Inhibitors: Current Role, Toxicity Management, and Future Frontiers in Immunosuppression

  2025cites this paper